Related Experiment Video
Updated: Jun 8, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Smac mimetics: implications for enhancement of targeted therapies in leukemia
1Department of Medical Oncology/Hematologic Neoplasia, Dana Farber Cancer Institute, Boston, MA 02115, USA. Ellen_Weisberg@dfci.harvard.edu
Abstract:
Drug resistance is a growing concern with clinical use of tyrosine kinase inhibitors. Utilizing in vitro models of intrinsic drug resistance and stromal-mediated chemoresistance, as well as functional mouse models of progressive and residual disease, we attempted to develop a potential therapeutic approach designed to suppress leukemia recurrence following treatment with selective kinase inhibitors. The novel IAP inhibitor, LCL161, [corrected] was observed to potentiate the effects of tyrosine kinase inhibition against leukemic disease both in the absence and presence of a stromal-protected [corrected] environment. LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease in vitro and potentiated the activity of both kinase inhibitors against leukemic disease in vivo. In addition, LCL161 synergized in vivo with nilotinib to reduce leukemia burden significantly below the baseline level suppression exhibited by a moderate-to-high dose of nilotinib. Finally, LCL161 displayed antiproliferative effects against cells characterized by intrinsic resistance to tyrosine kinase inhibitors as a result of expression of point mutations in the protein targets of drug inhibition. These results support the idea of using IAP inhibitors in conjunction with targeted tyrosine kinase inhibition to override drug resistance and suppress or eradicate residual disease.
Insights
This study shows that LCL161, an IAP inhibitor, enhances tyrosine kinase inhibitors like nilotinib against leukemia. This combination therapy overcomes drug resistance and reduces leukemia burden, offering hope for suppressing disease recurrence.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Drug resistance to tyrosine kinase inhibitors (TKIs) is a significant clinical challenge in leukemia treatment.
- Leukemia cells can develop intrinsic resistance or resistance mediated by the stromal microenvironment.
- Residual disease and recurrence remain critical issues despite targeted therapies.
Purpose of the Study:
- To investigate a novel therapeutic strategy combining an IAP inhibitor with TKIs to overcome drug resistance.
- To evaluate the efficacy of LCL161 in combination with nilotinib and PKC412 against resistant leukemia models.
- To assess the potential of this combination to suppress or eradicate residual leukemia and prevent recurrence.
Main Methods:
- Utilized in vitro models of intrinsic and stromal-mediated drug resistance.
- Employed functional mouse models of progressive and residual leukemia.
- Assessed the effects of LCL161 alone and in combination with nilotinib and PKC412 on leukemic cell apoptosis and proliferation.
- Evaluated in vivo leukemia burden reduction and synergistic effects.
Main Results:
- LCL161 potentiated the anti-leukemic effects of nilotinib and PKC412 in vitro and in vivo.
- The combination of LCL161 and nilotinib significantly reduced leukemia burden below baseline levels in vivo.
- LCL161 demonstrated antiproliferative activity against leukemia cells with intrinsic TKI resistance due to point mutations.
- LCL161 enhanced the pro-apoptotic effects of TKIs in both standard and stromal-protected environments.
Conclusions:
- Combining IAP inhibitors with TKIs is a promising strategy to overcome drug resistance in leukemia.
- LCL161 can synergize with TKIs to effectively reduce leukemia burden and target resistant cell populations.
- This approach holds potential for suppressing or eradicating residual disease and preventing leukemia recurrence.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...